- 著者
- YASUO IKEDA
- 出版者
- The Keio Journal of Medicine
- 雑誌
- The Keio Journal of Medicine (ISSN:00229717)
- 巻号頁・発行日
- vol.26, no.4, pp.213-222, 1977 (Released:2009-03-27)
- 参考文献数
- 14
- 被引用文献数
- 15 16
Effects of Ibuprofen, a non-steroidal anti-inflammatory drug, on platelet function were studied. Similar to aspirin, Ibuprofen inhibited both platelet release reaction and aggregation in vitro. However, the alteration of platelet function induced by the administration of a therapeutic dose of Ibuprofen in vivo was observed after 2 hours of its administration and disappeared usually within 24 hours. Aspirin-induced changes in platelet function have been known to continue as long as 7 days after a single dosage of aspirin. Prolongation of bleeding time was also noted with Ibuprofen. The platelet dysfunction thus induced by Ibuprofen was easily restored by washing the platelets in vitro, while aspirin-induced one remained unchanged by the same procedure. These results may suggest that Ibuprofen is responsible for easy bruises in its users and the mechanism by which induces the platelet dys-function is somewhat different from that by aspirin.
- 著者
- Takanari Kitazono Kazunori Toyoda Kazuo Kitagawa Takehiko Nagao Hiroshi Yamagami Shinichiro Uchiyama Norio Tanahashi Masayasu Matsumoto Kazuo Minematsu Izumi Nagata Masakatsu Nishikawa Shinsuke Nanto Yasuo Ikeda Toshiaki Shirai Kenji Abe Akira Ogawa PRASTRO-I Study Group
- 出版者
- Japan Atherosclerosis Society
- 雑誌
- Journal of Atherosclerosis and Thrombosis (ISSN:13403478)
- 巻号頁・発行日
- pp.56093, (Released:2020-06-04)
- 参考文献数
- 19
- 被引用文献数
- 10
Aims: The efficacy of antiplatelet therapy may vary among different disease subtypes. Prasugrel is generally a more potent, consistent, and fast-acting platelet inhibitor than clopidogrel. This sub-analysis of the phase III comparison of PRAsugrel and clopidogrel in Japanese patients with ischemic STROke (PRASTRO-I) trial aimed to assess the differences in efficacy of these treatments for each stroke subtype. Methods: In the PRASTRO-I trial, a total of 3,753 patients with ischemic stroke were recruited from 224 centers throughout Japan and randomized (1:1) to prasugrel (3.75 mg/day) or clopidogrel (75 mg/day) for 96 weeks. For the sub-analysis, strokes were classified as large-artery atherosclerosis, small-artery occlusion (lacunar), stroke of other etiology, and stroke of undetermined etiology. The cumulative incidence of primary events (ischemic stroke, myocardial infarction, and death from other vascular cause) and hazard ratios (HRs) were calculated for each subgroup. Results: For patients with large-artery atherosclerosis, the primary event incidence was 3.8% in the prasugrel group and 4.8% in the clopidogrel group (HR 0.79; 95% confidence interval [CI] 0.45–1.40). For patients with small-artery occlusion, the incidence was 3.3% in the prasugrel group and 3.9% in the clopidogrel group (HR 0.83; 95% CI 0.46–1.53). For patients with stroke of undetermined etiology, the incidence was 4.6% in the prasugrel group and 3.0% in the clopidogrel group (HR 1.56; 95% CI 0.90–2.72). The incidence of bleeding was similar across subtypes. Conclusions: Although statistical significance was not reached, the efficacy of prasugrel was potentially different between stroke subtypes, warranting further studies.